Global Psoriasis Therapeutics Market Size study & Forecast, by Drug Class (TNF Inhibitors, PDE4 Inhibitors, Interleukin Blockers, and Others), Molecule Type (Biologics, and Small Molecules), and by Route of Administration (Oral, Parenteral, and Topical) a

Global Psoriasis Therapeutics Market Size study & Forecast, by Drug Class (TNF Inhibitors, PDE4 Inhibitors, Interleukin Blockers, and Others), Molecule Type (Biologics, and Small Molecules), and by Route of Administration (Oral, Parenteral, and Topical) and Regional Analysis, 2022-2029

Global Psoriasis Therapeutics Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Psoriasis is a type of skin disorders which causes skins cells to replace more quickly than normal. Psoriasis is associated with immune system and most commonly occurs on knees, elbows, trunk, and scalp. The increasing incidences of Psoriasis disease and rising awareness towards different treatment options available as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to National Psoriasis Foundation, USA – as of 2020, around 8 million individuals in the United States are affected by Psoriasis. In addition, around 125 million people worldwide suffers from Psoriasis, witnessing for over 2 to 3 percent of the global population. Moreover, as per World Health Organization (WHO) estimates – approximately 100 million individuals worldwide are affected by Psoriasis. Also, rising healthcare infrastructure in emerging economies and increasing R&D activities in pharmaceuticals sector would create lucrative growth prospectus for the market over the forecast period. However, high treatment cost associated with Psoriasis treatment and health risks associated with medications impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Psoriasis Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the; leading region in terms of market share owing to presence of leading market players as well as increasing prevalence of Psoriasis in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising pharmaceuticals sector as well as increasing incidences of skin disorders in the region.

Major market player included in this report are:
Astellas Pharma Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
F. Hofffmann-La Roche
GlaxoSmithKline plc
Merck and Co., Inc.
Valeant Pharmaceuticals International, Inc.
Biocon Limited
Eli Lilly and Company
G and W Laboratories Inc.

Recent Developments in the Market:
In October 2021, India based Sun Pharmaceuticals Ltd. unveiled its medicine named ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis in Canada.

In December 2021, The Food and Drug Administration of USA has approved the expanded use of Amgen Inc's drug Otezla for the treatment of adults with mild to moderate plaque psoriasis. With this approval Otezla would be the first and only oral treatment option available for plaque psoriasis in adults.


Global Psoriasis Therapeutics Market Report Scope:
Historical DataCompanies Mentioned

Astellas Pharma Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
F. Hofffmann-La Roche
GlaxoSmithKline plc
Merck and Co., Inc.
Valeant Pharmaceuticals International, Inc.
Biocon Limited
Eli Lilly and Company
G and W Laboratories Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.